I've never seen so much scrutiny over a company before. Everyone is screaming "death to Theranos" at every opportunity. How much of that is purely balking over the high valuation? I have a feeling if they didn't raise so much money then journalists wouldn't be swarming this at all.

All of the critiques I see don't seem even close to show stoppers. No public peer reviewed studies? Some lab updates to match FDA regulations? Using some "unauthorized" third party equipment? This is a new company, why should these be the doomsday callings?

I have no idea if Theranos will succeed, but I can't shake the feeling that this media response is inflated due to the high valuation, and journalists are falling victim to the hype as much as the public, whereas this is a fairly normal health startup otherwise. It probably was a mistake to accept such a high valuation, so I don't think Theranos is totally innocent here.

It's also strange that a paywall article made it to the front page? I wouldn't guess there's a big overlap of WSJ subscribers and HN readers (lol conspiracy).